AI assistant
Sending…
Summit Therapeutics Inc. — Director's Dealing 2022
May 26, 2022
30436_dirs_2022-05-25_5071d844-66a9-4868-874f-ed4048cce2cb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2022-05-23
Reporting Person: DUGGAN ROBERT W (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-23 | Common Stock | J | 21135 | — | Acquired | 67683589 | Direct |
Footnotes
F1: The shares of Common Stock were collateral for a loan made by the Reporting Person to a third party, and were transferred to the Reporting Person in full satisfaction of the loan.
More from Summit Therapeutics Inc.
Interim / Quarterly Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 17
Annual Report
2026
Feb 23
Regulatory Filings
2026
Feb 23
Regulatory Filings
2026
Jan 29
Director's Dealing
2026
Jan 12
Regulatory Filings
2026
Jan 12
Director's Dealing
2026
Jan 7
Director's Dealing
2026
Jan 7
Director's Dealing
2026
Jan 7